Lewy body dementia
- Lewy body disease
- Diffuse Lewy body disease
- Autosomal dominant diffuse Lewy body disease
News & Events
On this page
ORDR Co-Sponsored Conferences
Third Genome Dynamics in the Neurosciences Conference, Sunday, July 18, 2010 - Thursday, July 22, 2010
Location: The Hilton Metropole, Brighton, England
Description: The goal of this meeting was to integrate basic processes of DNA damage signaling and repair and clinical aspects of neurological and neurodegenerative disease. The program was designed to bring together leading scientists with primary interests in DNA damage signaling with those working in specific related neurodegenerative disease areas as a means for integrating these fields. It was anticipated that this would generate insights into how normal processes of genome maintenance in the brain contribute to the prevention of a wide range of diseases.
Third NIH Workshop on Gaucher Disease and Parkinsonism, Thursday, April 08, 2010 - Friday, April 09, 2010
Location: NIH- the Cloister, Bethesda, Maryland
Description: Workshop goals were to (1) determine the appropriate human, animal, or cell-based models to better understand this correlation; (2) explore the mechanisms and/or pathways involved; and (3) establish international collaborations to enhance progress in the field and to make recommendations for future study.
Workshop on Glucocerebrosidase and the Synucleinopathies, 2004
Location: NIH Fogarty Center, Bethesda, MD
Description: Several new studies have reported evidence for an association between Gaucher disease, the inherited deficiency of glucocerebrosidase, and the synucleinopathies, clinically diverse neurodegenerative disorders characterized by fibrillar α-synuclein inclusions in neuronal and/or glial cell populations. Recently, several groups have reported findings that show an increased frequency of Gaucher mutations in patients with parkinsonism. This conference brought together basic researchers, pathologists, and clinicians from diverse backgrounds studying synucleinopathies and/or Gaucher disease to explore the etiology and significance of this association. The format included presentations from invited speakers and roundtable discussions. Agenda items included talks on clinical, natural history, animal, pathology, cell biology, protein, and molecular studies as well as discussions of strategies for future research and therapeutic advances. A consensus statement will be drafted for publication. Goals included (1) understanding the contribution of mutant glucocerebrosidase to the development of synucleinopathies, (2) better establishing the frequency of this association in different clinical cohorts and determining the relative risk of developing parkinsonism in Gaucher patients and heterozygotes, and (3) raising awareness of how heterozygosity for a rare disease may be a risk factor for common disorders.